The research involved 96 children who were randomly assigned to receive either antiviral treatment (pleconaril and ribavirin) or a placebo for six months shortly after their T1D diagnosis. After 12 months, the group receiving antiviral treatment had significantly higher levels of residual insulin production, which is essential for managing T1D. The study suggests that antiviral treatment may play a role in preserving beta cell function at the time of T1D diagnosis, offering hope for improved management of the condition. Further research is needed to explore this potential and determine if antiviral treatment can delay the progression of T1D. The results were published in Nature Medicine. For more Info, we refer to the press release.